Olumiant becomes the first oral medicine to bag approval by the Food and Drug Administration as a treatment for severe alopecia areata, an autoimmune disorder that affects the hair follicles and causes patchy baldness. This will be the first systemic treatment for alopecia areata, which was considered uncurable earlier on. Olumiant has to be used extremely cautiously due to the side effects it shows. Patients will be recommended to do close monitoring of symptoms of infection after the treatment.
Read More from FDA
English